Abstract
With phosphodiesterase inhibitors (PDE-Is) showing significant promise in shortening tuberculosis treatment, we assessed the effect of roflumilast, an FDA-approved type 4 PDE-I, in both acute and chronic murine models of tuberculosis. Alone, roflumilast had no effect on lung bacillary burden and mortality. However, when roflumilast was used in combination with isoniazid, a reduction in lung bacillary burden was observed. These data suggest that roflumilast may be a good candidate for tuberculosis host-directed therapy (HDT).
| Original language | English (US) |
|---|---|
| Pages (from-to) | 7888-7890 |
| Number of pages | 3 |
| Journal | Antimicrobial agents and chemotherapy |
| Volume | 59 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 1 2015 |
Funding
This work was supported by National Institutes of Health (NIH) grants A1079590, AI37856, and AI36973 (W.R.B), by the NIH, NIAID Division of Intramural Research (M.M.), and by the Howard Hughes Medical Institute (W.R.B). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
ASJC Scopus subject areas
- Pharmacology (medical)
- Infectious Diseases
- Pharmacology
